Correlation Between ZyVersa Therapeutics and Cullinan Oncology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ZyVersa Therapeutics and Cullinan Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ZyVersa Therapeutics and Cullinan Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ZyVersa Therapeutics and Cullinan Oncology LLC, you can compare the effects of market volatilities on ZyVersa Therapeutics and Cullinan Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ZyVersa Therapeutics with a short position of Cullinan Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of ZyVersa Therapeutics and Cullinan Oncology.

Diversification Opportunities for ZyVersa Therapeutics and Cullinan Oncology

0.67
  Correlation Coefficient

Poor diversification

The 3 months correlation between ZyVersa and Cullinan is 0.67. Overlapping area represents the amount of risk that can be diversified away by holding ZyVersa Therapeutics and Cullinan Oncology LLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cullinan Oncology LLC and ZyVersa Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ZyVersa Therapeutics are associated (or correlated) with Cullinan Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cullinan Oncology LLC has no effect on the direction of ZyVersa Therapeutics i.e., ZyVersa Therapeutics and Cullinan Oncology go up and down completely randomly.

Pair Corralation between ZyVersa Therapeutics and Cullinan Oncology

Given the investment horizon of 90 days ZyVersa Therapeutics is expected to under-perform the Cullinan Oncology. In addition to that, ZyVersa Therapeutics is 3.14 times more volatile than Cullinan Oncology LLC. It trades about -0.2 of its total potential returns per unit of risk. Cullinan Oncology LLC is currently generating about -0.24 per unit of volatility. If you would invest  1,737  in Cullinan Oncology LLC on August 18, 2024 and sell it today you would lose (351.00) from holding Cullinan Oncology LLC or give up 20.21% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

ZyVersa Therapeutics  vs.  Cullinan Oncology LLC

 Performance 
       Timeline  
ZyVersa Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Cullinan Oncology LLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cullinan Oncology LLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

ZyVersa Therapeutics and Cullinan Oncology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ZyVersa Therapeutics and Cullinan Oncology

The main advantage of trading using opposite ZyVersa Therapeutics and Cullinan Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ZyVersa Therapeutics position performs unexpectedly, Cullinan Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cullinan Oncology will offset losses from the drop in Cullinan Oncology's long position.
The idea behind ZyVersa Therapeutics and Cullinan Oncology LLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Other Complementary Tools

ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm